Read on Twitter
#IDTwitter #IDFellows
Introducing our new series: “IDFN top 10 articles every fellow should read”
#1: SAB management
by @mmcclean1 @LeMiguelChavez
Reviewers @KaBourgi, @IgeGeorgeMD, @Courtcita, @MDdreamchaser
We know is subjective & expect feedback/future improvements
Introducing our new series: “IDFN top 10 articles every fellow should read”
#1: SAB management
by @mmcclean1 @LeMiguelChavez
Reviewers @KaBourgi, @IgeGeorgeMD, @Courtcita, @MDdreamchaser
We know is subjective & expect feedback/future improvements
1. Clinical management of Staphylococcus aureus bacteremia: a review.
https://pubmed.ncbi.nlm.nih.gov/25268440/
A must read written by Holland et al. where they review the evidence of the management of SAB.
https://pubmed.ncbi.nlm.nih.gov/25268440/
A must read written by Holland et al. where they review the evidence of the management of SAB.
2. Impact of Infectious Disease Consultation on Quality of Care, Mortality, and Length of Stay in Staphylococcus aureus Bacteremia: Results From a Large Multicenter Cohort Study.
https://pubmed.ncbi.nlm.nih.gov/25701854/
ID consult associated with reduced inpatient mortality.
https://pubmed.ncbi.nlm.nih.gov/25701854/
ID consult associated with reduced inpatient mortality.
3. Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT): Scoring System to Guide Use of Echocardiography in the Management of Staphylococcus aureus Bacteremia
https://pubmed.ncbi.nlm.nih.gov/25810284/
Predictive risk factors for infective endocarditis, and thus the need for TEE.
https://pubmed.ncbi.nlm.nih.gov/25810284/
Predictive risk factors for infective endocarditis, and thus the need for TEE.
4. The Cefazolin Inoculum Effect Is Associated With Increased Mortality in Methicillin-Susceptible Staphylococcus aureus Bacteremia.
https://pubmed.ncbi.nlm.nih.gov/29977970/
Presence of cefazolin inoculum effect in the infecting isolate was associated with an increase 30-day mortality.
https://pubmed.ncbi.nlm.nih.gov/29977970/
Presence of cefazolin inoculum effect in the infecting isolate was associated with an increase 30-day mortality.
5. Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review.
https://pubmed.ncbi.nlm.nih.gov/28698037/
Similar outcomes for treatment of MSSA but more side effects with the anti-staphylococcal penicillins.
https://pubmed.ncbi.nlm.nih.gov/28698037/
Similar outcomes for treatment of MSSA but more side effects with the anti-staphylococcal penicillins.
6. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.
https://pubmed.ncbi.nlm.nih.gov/17173215/
Vancomycin had higher risk of treatment failure compared to cefazolin in MSSA BSI.
https://pubmed.ncbi.nlm.nih.gov/17173215/
Vancomycin had higher risk of treatment failure compared to cefazolin in MSSA BSI.
7. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
https://pubmed.ncbi.nlm.nih.gov/16914701/
RCT: dapto noninferior to SOC (B-lactams or vanco + gentamicin). Dapto resistance can emerge on treatment and more renal dysfunction in the SOC arm.
https://pubmed.ncbi.nlm.nih.gov/16914701/
RCT: dapto noninferior to SOC (B-lactams or vanco + gentamicin). Dapto resistance can emerge on treatment and more renal dysfunction in the SOC arm.
8. Adjunctive rifampicin for Staphylococcus aureus bacteremia (ARREST): a multicenter, randomized, double-blind, placebo-controlled trial.
https://pubmed.ncbi.nlm.nih.gov/29249276/
Rifampin addition not different to standard therapy in failure, recurrence or death.
https://pubmed.ncbi.nlm.nih.gov/29249276/
Rifampin addition not different to standard therapy in failure, recurrence or death.
9. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial. (CAMERA-2)
https://pubmed.ncbi.nlm.nih.gov/32044943/
more AKI with combination w/o benefit.
https://pubmed.ncbi.nlm.nih.gov/32044943/
more AKI with combination w/o benefit.
10. A Narrative Review of Early Oral Stepdown Therapy for the Treatment of Uncomplicated Staphylococcus aureus Bacteremia: Yay or Nay?
https://pubmed.ncbi.nlm.nih.gov/32523971/
Oral step-down therapy can be an alternative in some select patients without complicated SAB.
https://pubmed.ncbi.nlm.nih.gov/32523971/
Oral step-down therapy can be an alternative in some select patients without complicated SAB.
Which article did we miss, or you would include in this list?
@BCMIDFellowship @DartmouthID @OhioState_ID @BIDMC_IDFellows @Tufs_ID @IUIDfellowship @UAB_ID @yaleIDfellows @ID_musc
@BCMIDFellowship @DartmouthID @OhioState_ID @BIDMC_IDFellows @Tufs_ID @IUIDfellowship @UAB_ID @yaleIDfellows @ID_musc
@templeID1 @VUMC_IC @MayoclinicINFD @MGH_ID @UCLA_ID @MontefioreID @UNMC_ID @UVA_ID @OhioState_ID @UTSWinfDis @BrownIDprogram @RushCCH_ID @OHSU_ID
Also, check out this timeline of landmark trials.
Which trial would you like to add?
Which trial would you like to add?
Next in "IDFN top 10 articles every fellow should read”:
- Infective Endocarditis
Coming soon: Osteoarticular infx , Enterobacterales infx, Transplant ID and more.
Check out the next tweet if you want to be an author of this series.
- Infective Endocarditis
Coming soon: Osteoarticular infx , Enterobacterales infx, Transplant ID and more.
Check out the next tweet if you want to be an author of this series.
The IDFN is looking for content creators! Please retweet and share!
